Oncotelic Therapeutics, Inc. (OTCQB: OTLC) announced the completion of key Phase 2 objectives in its manufacturing automation initiative with TechForce Robotics, advancing the commercialization of an AI-powered good manufacturing practices (GMP) manufacturing services platform at SAPU Bio, the company’s 45%-owned sterile injectable cGMP manufacturing joint venture. The development marks a significant step in integrating artificial intelligence into pharmaceutical manufacturing.
The Phase 2 deployment expands the capabilities of Oncotelic’s proprietary PDAOAI platform across sterile manufacturing operations, electronic batch records, GMP workflow execution, cleanroom monitoring and autonomous materials movement. This integrated platform combines PDAOAI with TechForce’s autonomous robotic systems to support intelligent pharmaceutical manufacturing, creating potential opportunities in software licensing, automation deployment, manufacturing partnerships and technology-enabled contract development and manufacturing services (CDMO).
Oncotelic plans to demonstrate the platform at the BIO International Convention 2026 in San Diego as it pursues broader commercialization efforts within the pharmaceutical manufacturing sector. The company aims to leverage its expertise in AI and automation to address the growing demand for efficient, compliant manufacturing solutions in the pharmaceutical industry.
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on oncology and immunotherapy products, addressing high-unmet-need cancers and rare pediatric indications. The company benefits from a robust portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed over 500 patent applications and holds 75 issued patents. Oncotelic also leverages its proprietary AI-enabled PDAOAI platform, which supports research, biomarker discovery, and regulatory processes through advanced data analysis and knowledge integration.
Beyond its internal programs, Oncotelic licenses and co-develops select drug candidates through strategic partnerships and joint ventures. The company currently owns a 45% interest in GMP Bio, a joint venture advancing a complementary pipeline of therapeutic candidates that further strengthens Oncotelic’s position in oncology and rare disease therapeutics. The advancement of the AI-powered GMP manufacturing platform underscores Oncotelic’s commitment to innovation and its potential to transform pharmaceutical manufacturing through intelligent automation.